4.7 Article

Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia

期刊

JOURNAL OF CLINICAL ONCOLOGY
卷 21, 期 21, 页码 3928-3932

出版社

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2003.02.134

关键词

-

类别

向作者/读者索取更多资源

(Purpose) under bar. Rai's and Binet's staging systems have contributed significantly to the identification of major prognostic groups in chronic lymphocytic leukemic (CLL), though they fail to accurately predict disease progression at the individual level. Biologic factors, such as the mutational status of the immunoglobulin heavy-chain variable genes (VH, cytogenetics, CD38 expression, and some serum markers, have recently improved prognostic assessment in CLL. In this study, we analyzed the prognostic value of VH mutational status within the different stages of Binet's classification in 145 patients. (Patients and Materials) under bar: Our series consisted of 83 VH mutated (MT) and 62 VH unmutated (UM) patients. MT cases predominated within Binet's stage A (70%), whereas UM cases predominated among stages B and C (62%). (Results) under bar: Median overall survival (OS) was 84 months for UM patients and was not achieved for the MT group (70% 12-year survival, P < .0001). Concerning Binet's stage A, both median OS and progression-free survival were significantly shorter for UM patients when compared with those of MT patients (97 months v not achieved, P = .0017; and 42 v 156 months, P < .0001), which compared favorably with the classical A' and A'' substaging. The VH mutational profile could also segregate stage 5 and C patients into two groups with different survival patterns (median OS, 78 v 120 months for UM and MT patients, respectively, P =.002). (Conclusion) under bar: The significant survival differences observed between the VH mutational groups, among stage A and stage B and C patients, indicate that Binet's classification and VH genes are independent prognostic variables and are most likely complementary. (C) 2003 by American Society of Clinical Oncology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据